The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2017 | Novel agents for myeloma related bone disease
Evangelos Terpos, MD, PhD from the University of Athens, Athens, Greece discusses the major osteoclast inhibitors used to manage myeloma related bone disease. Zoledronic acid is a bisphosphonate that induces the apoptosis of osteoclasts, whereas denosumab inhibits the mechanism of action of osteoclasts. Zoledronic acid is the current standard treatment and more investigation into denosumab is required to decide which agent produces better patient and survival outcomes. Recorded at the European Hematology Association (EHA) 2017 Annual Congress in Madrid, Spain.
